Oncology News | pharmaphorum

News

AZ’s Tagrisso wins new NSCLC first-line approval in Europe

AstraZeneca has widened the licence for its cancer drug Tagrisso (osimertinib) in Europe after regulators gave it the green-light for first-line use against additional types of non-small ce

News

Lung cancer drug Keytruda to become routinely available on N...

NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment for certain patients in England.

News

Amgen faces first Neulasta biosimilar rival as FDA approves ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.

Event coverage

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi

News

Roche’s Perjeta combo approved in Europe for early breast ca...

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.

News

Bayer and MD Anderson collaborate on novel targeted cancer t...

Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.

AZ’s Tagrisso wins new NSCLC first-line approval in Europe

Lung cancer drug Keytruda to become routinely available on N...

Amgen faces first Neulasta biosimilar rival as FDA approves ...

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

Roche’s Perjeta combo approved in Europe for early breast ca...

Bayer and MD Anderson collaborate on novel targeted cancer t...

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks